Business Context and Reporting Period
This Form 8-K Current Report from Gain Therapeutics, Inc. (GANX) covers the Annual Meeting of Stockholders held on June 24, 2026. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The Annual Meeting addressed two primary matters:
- Election of Directors: Seven nominees were elected to one-year terms. All nominees received majority support, though significant broker non-votes were recorded.
- Ratification of Auditors: Stockholders approved the appointment of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
| Proposal | For | Against/Withheld | Abstain/Non-Vote |
|---|---|---|---|
| Election of Directors (Aggregate) | ~99.1M (Total For) | ~8.1M (Total Withheld) | 11,670,126 (Broker Non-Votes per nominee) |
| Ratification of Auditors | 25,865,468 | 1,074,319 | 40,462 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific term lengths and any potential conflicts of interest for the newly elected directors.
- Review the full proxy statement for details on the "Broker Non-Votes" which totaled over 11 million shares per director nominee.
- Check subsequent filings for the company's financial performance for the period ending June 24, 2026, as this 8-K contains no financial data.